Advertisement

Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival

Published:January 29, 2017DOI:https://doi.org/10.1016/j.ejso.2017.01.009

      Abstract

      Purpose

      Malignant peritoneal mesothelioma (MPM) is a rare disease with about 300 new cases per year in the USA. Its natural history is described as local progression within the peritoneal space in the absence of liver metastases or systemic disease.

      Methods

      Cytoreductive surgery (CRS) is a series of peritonectomy procedures and visceral resections with a goal of complete removal of all visible disease from the abdomen and pelvis. Over 20 years, three protocols investigating increasing efficacy of additional chemotherapy treatments added to CRS have been initiated. Initially, hyperthermic perioperative chemotherapy (HIPEC) with doxorubicin and cisplatin was used in the operating room. Then, early postoperative intraperitoneal chemotherapy (EPIC) with paclitaxel was added for the first 5 days after CRS. The third protocol employed HIPEC, then EPIC, and then long-term intraperitoneal (IP) paclitaxel or IP pemetrexed plus intravenous (IV) cisplatin as a adjuvant normothermic intraperitoneal chemotherapy (NIPEC).

      Result

      The 5-year survival of 42 patients treated with CRS and HIPEC was 44%, for 58 patients treated with EPIC and HIPEC was 52% and 29 patients who received HIPEC, EPIC, and NIPEC was 75% (p = 0.0374). Prognostic variables of age, gender, treatment administered, peritoneal cancer index (PCI) and completeness of cytoreduction were significant by univariate analysis and treatments administered and completeness of cytoreduction significant by multivariate analysis.

      Conclusions

      Long-term regional chemotherapy was associated with improved survival in patients with MPM. In this rare disease, additional phase 2 investigations are suggested.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Averbach A.M.
        • Sugarbaker P.H.
        Peritoneal mesothelioma: treatment approach based on natural history.
        in: Sugarbaker P.H. Peritoneal carcinomatosis: drugs and diseases. Kluwer, Boston1996: 193-212
        • Ma G.Y.
        • Bartlett D.L.
        • Reed E.
        • et al.
        Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
        Cancer J Sci Am. 1997; 3: 174-179
        • Park B.J.
        • Alexander H.R.
        • Libutti S.K.
        • et al.
        Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).
        Ann Surg Oncol. 1999; 6: 582-590
        • Mongero L.B.
        • Beck J.R.
        • Kroslowitz R.M.
        • Argenziano M.
        • Chabot J.A.
        Treatment of primary peritoneal mesothelioma by hyperthermic intraperitoneal chemotherapy.
        Perfusion. 1999; 14: 141-145
        • Loggie B.W.
        • Fleming R.A.
        • McQuellon R.P.
        • et al.
        Prospective trial for the treatment of malignant peritoneal mesothelioma.
        Am Surg. 2001; 67: 999-1003
        • Sugarbaker P.H.
        • Welch L.
        • Mohamed F.
        • et al.
        A review of peritoneal mesothelioma at the Washington Cancer Institute.
        Surg Oncol Clin N Am. 2003; 12: 605-621
        • Feldman A.L.
        • Libutti S.K.
        • Pingpank J.F.
        • et al.
        Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
        J Clin Oncol. 2003; 21: 4560-4567
        • Nonaka D.
        • Kusamura S.
        • Baratti D.
        • et al.
        Diffuse malignant mesothelioma of the peritoneum: a clinicopathological study of 35 patients treated locoregionally at a single institution.
        Cancer. 2005; 104: 2181-2188
        • Brigand C.
        • Monneuse O.
        • Mohamed F.
        • et al.
        Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
        Ann Surg Oncol. 2006; 13: 405-412
        • Elias D.
        • Bedard V.
        • Bouzid T.
        • et al.
        Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy.
        Gastroenterol Clin Biol. 2007; 31: 784-788
        • Yano H.
        • Moran B.J.
        • Cecil T.D.
        • et al.
        Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
        Eur J Surg Oncol. 2009; 35: 980-985
        • Yan T.D.
        • Welch L.
        • Black D.
        • et al.
        A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
        Ann Oncol. 2007; 18: 827-834
        • Helm J.H.
        • Miura J.T.
        • Glenn J.A.
        • et al.
        Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
        Ann Surg Oncol. 2015; 22: 1686-1693
        • Hassan R.
        • Alexander R.
        • Antman K.
        • et al.
        Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.
        Ann Oncol. 2006; 17: 1615-1619
        • Deraco M.
        • Bartlett D.
        • Kusamura S.
        • et al.
        Consensus statement on peritoneal mesothelioma.
        J Surg Oncol. 2008; 98: 268-272
      1. International PSOGI Registry on Peritoneal Mesothelioma. Accessible at http://test.dinamoweb.net/p_mesotelioma/.

        • Cerruto C.A.
        • Brun E.A.
        • Chang D.
        • et al.
        Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.
        Arch Pathol Lab Med. 2006; 130: 1654-1661
        • Deraco M.
        • Nonaka D.
        • Baratti D.
        • et al.
        Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
        Ann Surg Oncol. 2006; 13: 229-237
        • Yan T.D.
        • Haveric N.
        • Carmignani P.
        • et al.
        Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy.
        Cancer. 2005; 15: 839-849
        • Jacquet P.
        • Sugarbaker P.H.
        Current methodologies for clinical assessment of patients with peritoneal carcinomatosis.
        J Exp Clin Cancer Res. 1996; 15: 49-58
        • Yan T.D.
        • Yoo D.
        • Sugarbaker P.H.
        Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
        Eur J Surg Oncol. 2006; 32: 948-953
        • Baratti D.
        • Kusamura S.
        • Cabras A.D.
        • et al.
        Lymph node metastases in diffuse malignant peritoneal mesothelioma.
        Ann Surg Oncol. 2010; 17: 45-53
        • Yan T.D.
        • Edwards G.
        • Alderman R.
        • et al.
        Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma – a prospective study of 70 consecutive cases.
        Ann Surg Oncol. 2007; 14: 515-525
        • Sugarbaker P.H.
        Peritonectomy procedures.
        Ann Surg. 1995; 221: 29-42
        • Deraco M.
        • Baratti D.
        • Kusamura S.
        • et al.
        Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies.
        J Surg Oncol. 2009; 100: 321-328
        • Baratti D.
        • Kusamura S.
        • Cabras A.D.
        • et al.
        Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study.
        Ann Surg Oncol. 2012; 19: 1416-1424
        • Sugarbaker P.H.
        An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy.
        in: Sugarbaker P.H. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy. Textbook and video atlas. Cine-Med Publishing, Woodbury, CT2012: 1-30
        • Sugarbaker P.H.
        • Averbach A.M.
        • Jacquet P.
        • et al.
        A simplified approach to hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) using a self retaining retractor.
        in: Sugarbaker P.H. Peritoneal carcinomatosis: principles of management. Kluwer, Boston1996: 415-421
        • Van der Speeten K.
        • Stuart O.A.
        • Mahteme H.
        • et al.
        Pharmacokinetic study of perioperative intravenous ifosfamide.
        Int J Surg Oncol. 2011; 2011 (http://dx.doi.org/10.1155/2011/185092 9 pages)185092
        • Mohamed F.
        • Sugarbaker P.H.
        Intraperitoneal taxanes.
        Surg Oncol Clin N Am. 2003; 12: 825-833
        • Sugarbaker P.H.
        • Bijelic L.
        Adjuvant bidirectional chemotherapy using an intraperitoneal port.
        Gastroenterol Res Pract. 2012; 2012 (5 pages)752643
        • Bijelic L.
        • Stuart O.A.
        • Sugarbaker P.H.
        Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous cisplatin for diffuse malignant peritoneal mesothelioma.
        Gastroenterol Res Pract. 2012; 2012890450
        • Alberts D.S.
        • Liu P.Y.
        • Hannigan E.V.
        • et al.
        Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
        N Engl J Med. 1996; 335: 1950-1955
        • Markman M.
        • Bundy B.N.
        • Alberts D.S.
        • et al.
        Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
        J Clin Oncol. 2001; 19: 1001-1007
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • et al.
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N Engl J Med. 2006; 354: 34-43
        • Jacquet P.
        • Jelinek J.S.
        • Steves M.A.
        • et al.
        Evaluation of computer tomography in patients with peritoneal carcinomatosis.
        Cancer. 1993; 72: 1631-1636
        • Koh J.L.
        • Yan T.D.
        • Glenn D.
        • Morris D.L.
        Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis.
        Ann Surg Oncol. 2009; 16: 327-333
        • Ihemelandu C.
        • Bijelic L.
        • Sugarbaker P.H.
        Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal metastases: clinicopathologic characteristics and survival outcome.
        Ann Surg Oncol. 2015; 22: 1680-1685
        • Mohamed F.
        • Marchettini P.
        • Stuart O.A.
        • et al.
        Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
        Cancer Chemother Pharmacol. 2003; 52: 405-410
        • Sugarbaker P.H.
        • Turaga K.K.
        • Alexander Jr., H.R.
        • Deraco M.
        • Hesdorffer M.
        Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy.
        J Oncol Pract. 2016; 12: 928-935